We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 28, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Tariffs Cast Shadow on Abbott Labs' 2025 View: Time to Sell the Stock?
Abbott Laboratories has recorded a 15% rise in its share price year to date. Despite the company reporting a solid first-quarter 2025 earnings beat last week, external pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains. Let's delve deeper.
Since its earnings release on April 16, shares of Abbott have edged down 0.2%, underperforming the industry as well as the S&P 500’s gain of 2%. The broader Medical sector collectively gained 1% during this period. The company’s archrivals like Boston Scientific and Medtronic registered share price improvements of 6.2% and 2%, respectively, during the said period.
Tariffs Threaten Growth Trajectory
On the first-quarter earnings call, Abbott outlined the projected financial repercussions of U.S. tariffs imposed by the Trump administration. The company estimated the direct hit to be in the range of “a few hundred million dollars” for the current year. While the company claimed this figure would remain manageable in the near term, the concern lies in the longevity and unpredictability of tariff enforcement.
These tariffs are particularly consequential given that Abbott’s product portfolio, ranging from infant nutrition to advanced medical devices, relies heavily on global production and distribution networks. With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise, starting from the third quarter of 2025.
Defensive Strategy Might Improve Situation
While the trade policy environment introduces complexity, Abbott’s management remains confident about the company’s ability to weather the storm. The company’s global footprint with 90 manufacturing sites worldwide balances out the regional risks and gives the company scope to reroute supply chains when necessary. This diversified business model is expected to provide a degree of flexibility that the company’s peers may lack.
The company is currently studying long-term strategies to minimize tariff exposure. Options under consideration include leveraging its manufacturing base to localize production and avoid cross-border duties, optimizing supplier contracts and potentially passing on some of the increased costs to customers.
Two Impressive Long-Term Takeaways
EPD Set for Sustainable Growth: Abbott’s EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets. Focusing on the therapies most needed in the faster-growing markets, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%.
Abbott’s EPD sales in the first quarter of 2025 increased 8% organically. More than half of its top 15 markets posted double-digit gains. Abbott’s strategic focus on biosimilars further strengthens its prospects, with the company now securing rights to 15 biosimilar products across key therapeutic areas.
Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users. Lately, the company has been gaining momentum, leveraging consistent upgrades of FreeStyle Libre.
In 2024, Abbott obtained FDA approvals for two new over-the-counter continuous glucose monitoring systems called Lingo and Libre Rio, which are based on Libre’s technology, which is now used by more than 6 million people around the world. This over-the-counter availability of CGM marks the initiation of a new era for Abbott in the United States.In the first quarter, in Diabetes Care, sales of CGM exceeded $1.7 billion and grew 21.6%. Several products contributed to the strong performance, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet and AVEIR.
Long-Term Potential Hindered by Short-Term Weakness
Abbott is currently trading below its 50-day simple moving average (SMA) but above its 200-day SMA. While the company is experiencing short-term bearishness in the form of macro complexities, investors still think that it has potential for a long-term uptrend based on its fundamentals and growth strategies.
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 24.37X, a premium to the industry average of 21.07X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 14.47. However, Boston Scientific, with a current P/E of 34.08X, appears more stretched.
Our Take: Hold Now
Despite its adaptive strategies, Abbott's stock price has not fully reflected the company’s underlying strength. The subdued market reaction to its positive first-quarter results suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive performance in the first quarter boosted investor sentiment, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
For Immediate Release
Chicago, IL – April 28, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Tariffs Cast Shadow on Abbott Labs' 2025 View: Time to Sell the Stock?
Abbott Laboratories has recorded a 15% rise in its share price year to date. Despite the company reporting a solid first-quarter 2025 earnings beat last week, external pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains. Let's delve deeper.
Since its earnings release on April 16, shares of Abbott have edged down 0.2%, underperforming the industry as well as the S&P 500’s gain of 2%. The broader Medical sector collectively gained 1% during this period. The company’s archrivals like Boston Scientific and Medtronic registered share price improvements of 6.2% and 2%, respectively, during the said period.
Tariffs Threaten Growth Trajectory
On the first-quarter earnings call, Abbott outlined the projected financial repercussions of U.S. tariffs imposed by the Trump administration. The company estimated the direct hit to be in the range of “a few hundred million dollars” for the current year. While the company claimed this figure would remain manageable in the near term, the concern lies in the longevity and unpredictability of tariff enforcement.
These tariffs are particularly consequential given that Abbott’s product portfolio, ranging from infant nutrition to advanced medical devices, relies heavily on global production and distribution networks. With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise, starting from the third quarter of 2025.
Defensive Strategy Might Improve Situation
While the trade policy environment introduces complexity, Abbott’s management remains confident about the company’s ability to weather the storm. The company’s global footprint with 90 manufacturing sites worldwide balances out the regional risks and gives the company scope to reroute supply chains when necessary. This diversified business model is expected to provide a degree of flexibility that the company’s peers may lack.
The company is currently studying long-term strategies to minimize tariff exposure. Options under consideration include leveraging its manufacturing base to localize production and avoid cross-border duties, optimizing supplier contracts and potentially passing on some of the increased costs to customers.
Two Impressive Long-Term Takeaways
EPD Set for Sustainable Growth: Abbott’s EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets. Focusing on the therapies most needed in the faster-growing markets, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%.
Abbott’s EPD sales in the first quarter of 2025 increased 8% organically. More than half of its top 15 markets posted double-digit gains. Abbott’s strategic focus on biosimilars further strengthens its prospects, with the company now securing rights to 15 biosimilar products across key therapeutic areas.
Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users. Lately, the company has been gaining momentum, leveraging consistent upgrades of FreeStyle Libre.
In 2024, Abbott obtained FDA approvals for two new over-the-counter continuous glucose monitoring systems called Lingo and Libre Rio, which are based on Libre’s technology, which is now used by more than 6 million people around the world. This over-the-counter availability of CGM marks the initiation of a new era for Abbott in the United States.In the first quarter, in Diabetes Care, sales of CGM exceeded $1.7 billion and grew 21.6%. Several products contributed to the strong performance, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet and AVEIR.
Long-Term Potential Hindered by Short-Term Weakness
Abbott is currently trading below its 50-day simple moving average (SMA) but above its 200-day SMA. While the company is experiencing short-term bearishness in the form of macro complexities, investors still think that it has potential for a long-term uptrend based on its fundamentals and growth strategies.
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 24.37X, a premium to the industry average of 21.07X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 14.47. However, Boston Scientific, with a current P/E of 34.08X, appears more stretched.
Our Take: Hold Now
Despite its adaptive strategies, Abbott's stock price has not fully reflected the company’s underlying strength. The subdued market reaction to its positive first-quarter results suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive performance in the first quarter boosted investor sentiment, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Abbott currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.